Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
Cancer Chemotherapy and Pharmacology, 04/30/2012
Yoshimoto M et al. – Oral XC is an effective first– or second–line therapy for metastatic breast cancer (MBC), demonstrating high activity in both luminal A and triple–negative disease with few severe side effects. This metronomic oral combination chemotherapy could be beneficial for the treatment of HER2–negative MBC.
Patients received capecitabine 828mg/m2 twice daily with cyclophosphamide 33mg/m2 twice daily, days 1–14 every 3weeks.
The primary endpoint was overall response rate (ORR).
Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.
Between May 2007 and April 2009, 51 patients were enrolled and 45 were included in the efficacy analysis.
The median follow-up was 18.1months.
ORR was 44.4% and stable disease (≥24weeks) was achieved in 13.4%, resulting in a 57.8% clinical benefit response rate.
Median PFS was 12.3months (95% confidence interval: 8.9-18.9months).
Median PFS was 10.7months in triple-negative disease and 13.2months in estrogen-receptor positive, HER2-negative disease.
The 1- and 2-year OS rates were 86 and 71%, respectively.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.